Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161475 | 0.81 | ROCK2 (0.43) | ROCK2 | |
| SCHEMBL1013646 | 0.81 | ROCK2 (0.47) | ROCK2 | |
| SCHEMBL29470914 | 0.81 | ROCK2 (0.47) | ROCK2 | |
| SCHEMBL28005452 | 0.79 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL19809959 | 0.76 | ALOX5AP (0.35) | — | |
| SCHEMBL28213747 | 0.75 | ROCK2 (0.45) | ROCK2 | |
| SCHEMBL28796938 | 0.74 | ROCK2 (0.36) | ROCK2 | |
| SCHEMBL26981251 | 0.73 | ROCK2 (0.46) | ROCK2 | |
| SCHEMBL14663496 | 0.72 | ROCK2 (0.41) | ROCK2 | |
| SCHEMBL21331820 | 0.72 | ROCK2 (0.64) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024067649-A1 | DIAMINE COMPOUND, POLYIMIDE ACID, POLYIMIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 比亚迪股份有限公司 | 2024-04-04 | — | — | WO | claimed |
| WO-2024067649-A1 | DIAMINE COMPOUND, POLYIMIDE ACID, POLYIMIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 比亚迪股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024002328-A1 | NITROGEN-CONTAINING COMPOUND AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230406865-A1 | CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| EP-4245757-A1 | CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-11192886-B2 | S1P1 agonist and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-11180501-B2 | Crystal form of β-lactamase inhibitor and preparation method therefor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11078194-B2 | Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| EP-3492465-B1 | S1P1 AGONIST AND APPLICATION THEREOF | SHIJIAZHUANG SAGACITY NEW DRUG DEV CO LTD (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-20200385385-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2020-12-10 | — | — | US | disclosed |
| US-20200361913-A1 | SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-11-19 | — | — | US | disclosed |
| EP-3722282-A1 | SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-10-14 | — | — | EP | disclosed |
| EP-3719020-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | Qilu Pharmaceutical Co., Ltd (CN) | 2020-10-07 | — | — | EP | disclosed |
| EP-3492465-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192886-B2 | S1P1 agonist and application thereof | S1PR1, S1PR2, S1PR3 | ROCK2 828/4885 |
| US-11180501-B2 | Crystal form of β-lactamase inhibitor and preparation method therefor | NOTUM, MRPL21, BPHL | ROCK2 2421/4885 |
| US-20200385385-A1 | CRYSTAL FORM OF ß-LACTAMASE INHIBITOR AND PREPARATION METHOD THEREFOR | NOTUM, BPHL, DCXR | ROCK2 2519/4885 |
| US-11078194-B2 | Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor | FGFR1, FLT1, FGFR4 | ROCK2 193/4885 |
| US-20230406865-A1 | CRYSTAL FORM OF FREE BASE OF INHIBITOR CONTAINING BICYCLIC RING DERIVATIVE AND PREPARATION METHOD AND APPLICATION OF CRYSTAL FORM | RET, BRAF, PYGL | ROCK2 248/4885 |
| US-20200361913-A1 | SALT FORM AND CRYSTAL FORM SERVING AS FGFR AND VEGFR INHIBITOR COMPOUNDS, AND PREPARATION METHOD THEREFOR | FGFR1, FLT1, FGFR4 | ROCK2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.